Cryoport, Inc. key statistics and ratios

In fiscal 2025, Cryoport, Inc. had return on equity of 17.3%, an operating margin of -20.9%, debt equal to 37.1% of equity and a current ratio of 2.17. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cryoport, Inc.: financial ratios, annual
Fiscal year	2011Mar 2011	2012Mar 2012	2013Mar 2013	2014Mar 2014	2015Mar 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Gross margin	—	—	−44.3%	16.4%	29.7%	40.4%	49.9%	52.2%	51.1%	46.2%	43.4%	43.8%	44.7%	44.4%	47.1%	47.1%
Operating margin	<−999%	<−999%	−574.7%	−190.9%	−142.1%	−114.2%	−66.0%	−44.0%	−52.1%	−38.1%	−8.0%	−13.4%	−59.6%	−77.6%	−20.9%	−21.2%
Net margin	<−999%	<−999%	−579.9%	−735.6%	−178.6%	−170.8%	−66.1%	−48.7%	−54.0%	−41.5%	−123.8%	−15.7%	−59.0%	−73.2%	44.4%	−20.1%
Free-cash-flow margin	<−999%	<−999%	−449.0%	−169.9%	−106.7%	−88.3%	−44.3%	−31.9%	−19.6%	−30.2%	−7.1%	−10.1%	−23.4%	−21.4%	−14.2%	−10.7%
Return on equity	−103.4%	−161.9%	—	—	—	—	−67.0%	−33.9%	−22.2%	−12.8%	−53.8%	−6.2%	−19.1%	−25.8%	17.3%	−7.5%
Return on assets	−55.8%	−90.8%	−160.2%	<−999%	−325.6%	−244.7%	−55.7%	−24.9%	−19.0%	−9.5%	−33.1%	−3.5%	−10.0%	−13.8%	10.7%	−4.9%
Asset turnover	0.04	0.06	0.28	1.53	1.82	1.43	0.84	0.51	0.35	0.23	0.27	0.22	0.17	0.19	0.24	0.25
Current ratio	3.09	4.63	0.38	0.28	0.72	2.73	7.85	16.91	18.85	4.20	16.26	14.79	11.73	5.29	2.17	2.08
Debt to equity	40.4%	9.1%	—	—	—	0.0%	0.0%	38.2%	0.0%	30.0%	63.0%	73.2%	77.4%	49.4%	37.1%	38.1%
Interest cover (operating income ÷ interest)	n/m	n/m	n/m	n/m	n/m	n/m	n/m	n/m	n/m	n/m	n/m	n/m	n/m	n/m	n/m	n/m
R&D as % of revenue	94.5%	88.5%	38.7%	15.4%	9.0%	7.8%	10.1%	9.4%	11.0%	12.1%	7.6%	6.6%	10.7%	11.3%	9.7%	9.5%
SG&A as % of revenue	908.6%	>999%	491.7%	192.0%	162.9%	—	—	—	92.2%	72.3%	43.8%	50.6%	64.2%	70.0%	58.4%	58.8%
Capital spending as % of revenue	71.8%	47.3%	14.2%	5.2%	1.8%	13.8%	14.3%	14.8%	15.7%	11.3%	10.7%	9.3%	23.0%	11.0%	9.3%	15.0%
Free cash flow ÷ net income	—	—	—	—	—	—	—	—	—	—	—	—	—	—	−32.0%	—

US$ thousands unless shown otherwise. Fiscal quarters.

Cryoport, Inc.: financial ratios, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Gross margin	45.5%	47.0%	45.4%	47.0%	48.2%	47.8%	45.8%	46.6%
Operating margin	−34.9%	−30.7%	−17.5%	−21.2%	−22.5%	−22.1%	−20.1%	−20.5%
Net margin	2.1%	−45.1%	−29.2%	239.5%	−15.7%	−25.6%	−22.1%	−16.9%
Free-cash-flow margin	−9.9%	−25.8%	−18.3%	−25.7%	−2.9%	−10.0%	−13.1%	−16.3%
Current ratio	5.70	5.29	5.56	16.24	15.77	2.17	2.09	2.08
Debt to equity	0.3%	0.3%	0.3%	0.3%	0.3%	0.2%	0.2%	0.2%
R&D as % of revenue	10.8%	10.0%	9.6%	9.1%	10.2%	9.8%	8.2%	9.9%
SG&A as % of revenue	69.6%	67.8%	53.4%	59.2%	60.4%	60.0%	57.8%	57.2%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

6 of 7 checks passed · June 30, 2026

What it owns · $756m

Short-term assets $460mLonger-term assets $296m

What it owes, and who funded it · $756m

Short-term liabilities $221mLonger-term liabilities $44mShareholders' equity $491m

Short-term assets cover short-term liabilities $460m of assets due within a year against $221m of liabilities due within a year.
Short-term assets cover long-term liabilities $460m short-term assets against $44m of longer-dated liabilities.
More cash than debt $269m of cash against $985,000 of debt.
Debt below 40% of shareholders' equity Debt is 0% of equity.
Debt burden no higher than five years ago Debt to equity moved from 0% to 0% over five years.
A year's operating cash flow covers at least 20% of debt $8m of operating cash flow against $985,000 of debt.
Operating profit covers interest at least five times over Operating income of −$40m against $2m of interest.

From Cryoport, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

19 /100

Weak moat

How hard Cryoport's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 0 / 20

Cash operating profit has been a median -4.5% of total assets over 10 years.
Pricing power 14 / 20

Gross margin has been a median 45.6%, moving by 3.7 percentage points (standard deviation) across 10 years.
Durability 10 / 20

Operating margin has been a median -29.8%; its worst year was -133.3%.
Cash conversion 0 / 20

Free cash flow was positive in 0 of 10 years, at a median -20.5% of revenue.
Discipline 0 / 20

The diluted share count rose 19.3% over five years; stock-based pay has been a median 11.5% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (24 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: CTKB vs CYRX CYRX vs MRVI CYRX vs GRAL CYRX vs PACB

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Cryoport, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cryoport, Inc.